by Gonzalo Payan | Aug 27, 2020
We are very pleased to announce the award of a Small Business Innovation Research (SBIR) Phase I grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in support of our drug development program for Nonalcoholic Steatohepatitis (NASH),...by Gonzalo Payan | Mar 5, 2020
MAX BioPharma, Inc. recently published an article describing its anti-tumorigenic oxysterol lead compound, Oxy210, in the peer-reviewed journal, Cells. (https://www.mdpi.com/2073-4409/8/10/1297/pdf). Oxy210 is derived from the Company’s Oxysterol...by Gonzalo Payan | Nov 4, 2019
MAX BioPharma, Inc. recently published two articles describing its anti-tumorigenic oxysterol lead compounds in the peer-reviewed journal, Cells. Oxy186 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562610/) and Oxy210 (https://www.mdpi.com/2073-4409/8/10/1297/pdf)...by Gonzalo Payan | Oct 22, 2019
MAX BioPharma scientists publish new paper titled “Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling” as they progress their oncology program targeting lung cancer. Paper...by Gonzalo Payan | Jun 19, 2019
MAX BioPharma scientists publish new paper titled “Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties”. Paper available from https://www.mdpi.com/2073-4409/8/5/509...